Selected Grants
CA224123] A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Bristoll Myers Squibb · 2022 - 2027Molecular Determinants of Health Disparities in Inflammatory Breast Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2026[DP-1111-02CT] A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard
Clinical TrialPrincipal Investigator · Awarded by ITM Solucin GmbH · 2022 - 2026An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, with or without BI 754091, in Patients with Stage IV Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by AMAL Therapeutics S.A. · 2021 - 2026Phase Ib/II Study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)
Clinical TrialPrincipal Investigator · Awarded by Merck · 2017 - 2025CA224123] A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Bristoll Myers Squibb · 2022 - 2027Molecular Determinants of Health Disparities in Inflammatory Breast Cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2026[DP-1111-02CT] A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard
Clinical TrialPrincipal Investigator · Awarded by ITM Solucin GmbH · 2022 - 2026An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, with or without BI 754091, in Patients with Stage IV Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by AMAL Therapeutics S.A. · 2021 - 2026Phase Ib/II Study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)
Clinical TrialPrincipal Investigator · Awarded by Merck · 2017 - 2025A Phase III Randomized, Double-Blind, Placebo Controlled, Multi-centre Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2019 - 2024A phase I/2 open label study of Nivolumab monotherapy or Nivolmab combined with Ipilmumab in subjects with advanced or metastatic solid tumors.
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2013 - 2024Preventing Inflammatory Breast Cancer Metastases by Interrupting Cellular Stress Signaling in Lymphatic Emboli and Circulating Tumor Cell Clusters
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2024Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2024A Phase 1/2 open label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors.
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2024A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2018 - 2023Detection and Elimination of Oncogenic Signaling Networks in Pre-malignant and Malignant Cells with Magnetic Resonance Imaging
ResearchClinical Investigator · Awarded by Department of Defense · 2012 - 2022Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy
ResearchCo Investigator · Awarded by Department of Defense · 2012 - 2022Translational Research in Surgical Oncology
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2002 - 2022Characterization of Tumor Immunobiological Factors that Promote Lymphovascular Invasion and Dissemination in Locally Advanced Breast Cancer
ResearchCo Investigator · Awarded by Department of Defense · 2017 - 2022Phase Ib/II Study of Pembrolizumab with Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)
Clinical TrialPrincipal Investigator · Awarded by Ipsen Biopharmaceuticals, Inc. · 2016 - 2022A Study of fafety tolerabolity and clinical activitiy of MEDI4736 and Tremelimumab administered as monotherapy and in combination to subjects with unresectable heptocellular carcinoma
Clinical TrialPrincipal Investigator · Awarded by MedImmune, Inc. · 2015 - 2021A pilot study of active immunotherapy with CEA (6D) VRP vaccine (AVX701) in patients with stage III colon cancer.
Clinical TrialPrincipal Investigator · Awarded by AlphaVax, Inc. · 2013 - 2021A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Studyof Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellula
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2019 - 2021An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Clinical TrialPrincipal Investigator · Awarded by H3 Biomedicine, Inc. · 2018 - 2021A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECOND-LINE SYSTEMIC THERAPY
Clinical TrialPrincipal Investigator · Awarded by ASLAN Pharmaceuticals · 2017 - 2020A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Ge
Clinical TrialPrincipal Investigator · Awarded by Halozyme, Inc. · 2018 - 2020A Phase I dose escalation and cohort expansion study of ERY974
ResearchPrincipal Investigator · Awarded by Chugai Pharmaceutical Company, Ltd. · 2016 - 2020A Phase 1 multicenter, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors
Clinical TrialPrincipal Investigator · Awarded by PsiOxus Therapeutics Ltd. · 2018 - 2020A multicenter rendomized open label phase 3 trial to compare the efficacy and safety of Lenvatinib versus Sorafenib in first line treatment of subject with unresectable hepatocellular carcinoma.
Clinical TrialPrincipal Investigator · Awarded by Eisai, Inc. · 2013 - 2019A Phase III study of pemborlizumab (MK-3475) vs chemotherapy in microstatellite instablility - High (MSI-H) or mismatch repair deficienct (dMMR) stage IV colorectal carcinoma (Keynote - 177)
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2016 - 2018A phase 2B randomized controlled multicenter open-label study of the efficacy and immune responsoe of GVAX pancreas vaccine with cyclophosphamide and CRS-207 compared to chemotherapy
Clinical TrialPrincipal Investigator · Awarded by Aduro BioTech · 2014 - 2018Targeting the WNT/beta-catenin Pathway in Triple Negative Breast Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2013 - 2018An Open label single arm phase I study of the pahramcokinetics and safety of Carfilzomib in subjects with advanced malignancies and varing degrees of hepatic impairment.
Clinical TrialPrincipal Investigator · Awarded by Onyx Pharmaceuticals, Inc · 2013 - 2018Long term follow up of subject who participated in aduro sponsored protocols
Clinical TrialPrincipal Investigator · Awarded by Aduro BioTech · 2015 - 2017Novel Immune Modulating Cellular Vaccine for Prostate Cancer Immunotherapy
ResearchCo Investigator · Awarded by Department of Defense · 2013 - 2017A Phase 3 randomized placebo contolled parellel-group multicenter double blined study to evaluate the efficacy and safetyof Telotristat Etiprate
Clinical TrialPrincipal Investigator · Awarded by Lexicon Pharmaceuticals · 2014 - 2015Using Aptamer Coated Nanoparticles Encapsulating Prostate Tumor Antigen Encoding mRNA to Target Dendritic Cells In Vivo
ResearchCollaborator · Awarded by Department of Defense · 2012 - 2015Clinical Oncology Research Career Development Program
ResearchMentor · Awarded by National Institutes of Health · 2009 - 2015Targeting hCG-beta for Breast Cancer Immunotherapy
ResearchProject Leader · Awarded by National Institutes of Health · 2004 - 2009Vaccination with Regulatory T Cell Depletion
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2008Biomarker Studies for Novel Anti-Cancer Agents
ResearchCo Investigator · Awarded by National Institutes of Health · 2003 - 2008Immunotherapy using peptide MHC tetramer isolated Tcells
ResearchInvestigator · Awarded by National Institutes of Health · 2002 - 2007Dendritic Cell Mobilization and Active Immunotherapy
ResearchInvestigator · Awarded by National Institutes of Health · 2001 - 2007Planning a Duke Academic Public Private Partnership Program (AP4) Center
Institutional SupportCollaborator · Awarded by National Cancer Institute · 2004 - 2006Cancer Care Quality Measures: Diagnosis and Treatment of Colorectal Cancer
ResearchInvestigator · Awarded by Agency for Healthcare Research and Quality · 2004 - 2005Dexasome Based Immunotherapy of Lung Cancer
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2004Immunotherapy with TRICOM Modified Dendritic Cells
Clinical TrialInvestigator · Awarded by National Institutes of Health · 2001 - 2003External Relationships
- Alphasites
- AstraZeneca
- Cardinal Health, Inc.
- Eisai Pharmaceuticals
- Exelixis, Inc.
- Alphasites
- AstraZeneca
- Cardinal Health, Inc.
- Eisai Pharmaceuticals
- Exelixis, Inc.
- Genentech, Inc (Roche Holding)
- Gerson Lehrman Group, Inc.
- Guidepoint Global
- Health Advances
- ICON
- IPSEN Innovation
- MEDACorp (Leerink Swann & Co)
- PPD, Inc.
- Protagonist Therapeutics
- Quintiles / IQvia
- Regeneron Pharmaceuticals
- Schlesinger Associates
- Seagen
- Servier
- Society for immunotherapy of cancer
- Taiho
- Up To Date Inc/Wolters Kluwer Health
- Yiviva
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.